Acute Agitation and Aggression Therapeutics Market - Global Outlook and Forecast 2022-2028

March 2022 | 60 pages | ID: A296B087C878EN
Market Monitor Global

Abstracts

With acute agitation and aggression being a common symptom among patients suffering from various types of mental illnesses, the healthcare industry is expending efforts towards developing effective panaceas.

This report contains market size and forecasts of Acute Agitation and Aggression Therapeutics in Global, including the following market information:

Global Acute Agitation and Aggression Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Acute Agitation and Aggression Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Acute Agitation and Aggression Therapeutics include Eli Lilly and Company, Pfizer, Ono Pharmaceutical, Otsuka Holdings, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and H. Lundbeck A/S, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acute Agitation and Aggression Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Acute Agitation and Aggression Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Acute Agitation and Aggression Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Oral
• Intramuscular Injection
• Others

Global Acute Agitation and Aggression Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Acute Agitation and Aggression Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospitals & Ambulatory Surgical Centers
• Psychiatric Care Facilities
• Others

Global Acute Agitation and Aggression Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Acute Agitation and Aggression Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Acute Agitation and Aggression Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Acute Agitation and Aggression Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eli Lilly and Company
• Pfizer
• Ono Pharmaceutical
• Otsuka Holdings
• GlaxoSmithKline
• Bristol-Myers Squibb
• Johnson & Johnson
• H. Lundbeck A/S

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Acute Agitation and Aggression Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Acute Agitation and Aggression Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ACUTE AGITATION AND AGGRESSION THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Acute Agitation and Aggression Therapeutics Market Size: 2021 VS 2028
2.2 Global Acute Agitation and Aggression Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Acute Agitation and Aggression Therapeutics Players in Global Market
3.2 Top Global Acute Agitation and Aggression Therapeutics Companies Ranked by Revenue
3.3 Global Acute Agitation and Aggression Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Acute Agitation and Aggression Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Acute Agitation and Aggression Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Acute Agitation and Aggression Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Acute Agitation and Aggression Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Acute Agitation and Aggression Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Acute Agitation and Aggression Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Oral
  4.1.3 Intramuscular Injection
  4.1.4 Others
4.2 By Type - Global Acute Agitation and Aggression Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Acute Agitation and Aggression Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Acute Agitation and Aggression Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Acute Agitation and Aggression Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospitals & Ambulatory Surgical Centers
  5.1.3 Psychiatric Care Facilities
  5.1.4 Others
5.2 By Application - Global Acute Agitation and Aggression Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Acute Agitation and Aggression Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Acute Agitation and Aggression Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Acute Agitation and Aggression Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Acute Agitation and Aggression Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Acute Agitation and Aggression Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Acute Agitation and Aggression Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Acute Agitation and Aggression Therapeutics Revenue, 2017-2028
  6.3.2 US Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.3.3 Canada Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Acute Agitation and Aggression Therapeutics Revenue, 2017-2028
  6.4.2 Germany Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.4.3 France Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.4.5 Italy Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.4.6 Russia Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Acute Agitation and Aggression Therapeutics Revenue, 2017-2028
  6.5.2 China Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.5.3 Japan Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.5.6 India Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Acute Agitation and Aggression Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Acute Agitation and Aggression Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.7.3 Israel Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Acute Agitation and Aggression Therapeutics Market Size, 2017-2028
  6.7.5 UAE Acute Agitation and Aggression Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Eli Lilly and Company
  7.1.1 Eli Lilly and Company Corporate Summary
  7.1.2 Eli Lilly and Company Business Overview
  7.1.3 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.1.4 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Eli Lilly and Company Key News
7.2 Pfizer
  7.2.1 Pfizer Corporate Summary
  7.2.2 Pfizer Business Overview
  7.2.3 Pfizer Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.2.4 Pfizer Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Pfizer Key News
7.3 Ono Pharmaceutical
  7.3.1 Ono Pharmaceutical Corporate Summary
  7.3.2 Ono Pharmaceutical Business Overview
  7.3.3 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.3.4 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Ono Pharmaceutical Key News
7.4 Otsuka Holdings
  7.4.1 Otsuka Holdings Corporate Summary
  7.4.2 Otsuka Holdings Business Overview
  7.4.3 Otsuka Holdings Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.4.4 Otsuka Holdings Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Otsuka Holdings Key News
7.5 GlaxoSmithKline
  7.5.1 GlaxoSmithKline Corporate Summary
  7.5.2 GlaxoSmithKline Business Overview
  7.5.3 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.5.4 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 GlaxoSmithKline Key News
7.6 Bristol-Myers Squibb
  7.6.1 Bristol-Myers Squibb Corporate Summary
  7.6.2 Bristol-Myers Squibb Business Overview
  7.6.3 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.6.4 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Bristol-Myers Squibb Key News
7.7 Johnson & Johnson
  7.7.1 Johnson & Johnson Corporate Summary
  7.7.2 Johnson & Johnson Business Overview
  7.7.3 Johnson & Johnson Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.7.4 Johnson & Johnson Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Johnson & Johnson Key News
7.8 H. Lundbeck A/S
  7.8.1 H. Lundbeck A/S Corporate Summary
  7.8.2 H. Lundbeck A/S Business Overview
  7.8.3 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Major Product Offerings
  7.8.4 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 H. Lundbeck A/S Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Acute Agitation and Aggression Therapeutics Market Opportunities & Trends in Global Market
Table 2. Acute Agitation and Aggression Therapeutics Market Drivers in Global Market
Table 3. Acute Agitation and Aggression Therapeutics Market Restraints in Global Market
Table 4. Key Players of Acute Agitation and Aggression Therapeutics in Global Market
Table 5. Top Acute Agitation and Aggression Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Acute Agitation and Aggression Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Acute Agitation and Aggression Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Acute Agitation and Aggression Therapeutics Product Type
Table 9. List of Global Tier 1 Acute Agitation and Aggression Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Acute Agitation and Aggression Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Acute Agitation and Aggression Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Acute Agitation and Aggression Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Acute Agitation and Aggression Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Acute Agitation and Aggression Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Eli Lilly and Company Corporate Summary
Table 31. Eli Lilly and Company Acute Agitation and Aggression Therapeutics Product Offerings
Table 32. Eli Lilly and Company Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Acute Agitation and Aggression Therapeutics Product Offerings
Table 35. Pfizer Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Ono Pharmaceutical Corporate Summary
Table 37. Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Product Offerings
Table 38. Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Otsuka Holdings Corporate Summary
Table 40. Otsuka Holdings Acute Agitation and Aggression Therapeutics Product Offerings
Table 41. Otsuka Holdings Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline Corporate Summary
Table 43. GlaxoSmithKline Acute Agitation and Aggression Therapeutics Product Offerings
Table 44. GlaxoSmithKline Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Bristol-Myers Squibb Corporate Summary
Table 46. Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Product Offerings
Table 47. Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Johnson & Johnson Corporate Summary
Table 49. Johnson & Johnson Acute Agitation and Aggression Therapeutics Product Offerings
Table 50. Johnson & Johnson Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. H. Lundbeck A/S Corporate Summary
Table 52. H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Product Offerings
Table 53. H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Acute Agitation and Aggression Therapeutics Segment by Type in 2021
Figure 2. Acute Agitation and Aggression Therapeutics Segment by Application in 2021
Figure 3. Global Acute Agitation and Aggression Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Acute Agitation and Aggression Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Acute Agitation and Aggression Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Acute Agitation and Aggression Therapeutics Revenue in 2021
Figure 8. By Type - Global Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Acute Agitation and Aggression Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Acute Agitation and Aggression Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Eli Lilly and Company Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Otsuka Holdings Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Johnson & Johnson Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)